I haven’t done one of these for a while. The CoOVID-19 publication epidemic has continued at a rate of knots and there is lots of stuff to give us a laugh.
So you may not be surprised that COVID-19 in the UK and USA has made us rush to the drinks cabinet
Problem drinking before and during the COVID-19 crisis in US and UK adults: Evidence from two population-based longitudinal studies
Michael Daly, Eric Robinsondoi: https://doi.org/10.1101/2020.06.25.20139022
Whats this this got to do with MS..yet nothing and you may ask what has this got to do with MS….Well it is relevant to anti-CD20. It is interesting how it is seen in other conditions.
Several reports suggest a more prolonged disease in patients under rituximab, a B cell depleting drug.
Tepasse P-R, Hafezi W, Lutz M, Kühn J, Wilms C, Wiewrodt R, et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol. 1 juin 2020;2.
Avouac J, Airó P, Carlier N, Matucci-Cerinic M, Allanore Y. Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. Ann Rheum Dis. 5 juin 2020;
Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ, et al. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Ann Rheum Dis. 20 avr 2020; Acce
Increased risk for severe COVID–19 in patients with inflammatory rheumatic diseases treated with rituximab.Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A.Ann Rheum Dis. 2020 Jun 26:annrheumdis-2020-218075.
Whilst this is a letter about some people that died from COVID (both over 70 years old) It says “Our patients are not the unfortunate exceptions in that a substantial proportion of patients with inflammatory rheumatic diseases treated with rituximab require hospitalisation when infected with SARS-CoV-2 (eg, 67% of the patients in the National Registry for patients with IRD infected with SARS-CoV-2 in Germany) (Hasseli et al, submitted for publication, 2020)”.
Extending rituximab dosing intervals in patients with MS during the COVID–19 pandemic and beyond?Maarouf A, Rico A, Boutiere C, Perriguey M, Demortiere S, Pelletier J, Audoin B; Under the aegis of OFSEP.Neurol Neuroimmunol Neuroinflamm. 2020 Jun 25;7(5):e825. doi: 10.1212/NXI.0000000000000825. Print 2020 Sep.PMID: 32587103